Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 615 clinical trials
Role of Lymphnode Dissection in Men With Prostate Cancer Treated With Radical Prostatectomy

It allows the assessment of possible but unlikely lymph nodes metastases. In case of lymph node metastasis, depending on the number of affected lymph nodes, an adjuvant radiation with or without additional hormone therapy may be discussed in order to stop or delay further progression of the disease.

adjuvant
prostatectomy
lymph node metastases
cancer
endocrine therapy
  • 0 views
  • 19 Feb, 2024
  • 1 location
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

fitusiran
haemophilia a
antihemophilic factor
bethesda assay
factor ix
  • 0 views
  • 19 Feb, 2024
  • 11 locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

fitusiran
haemophilia a
antihemophilic factor
bethesda assay
factor ix
  • 0 views
  • 19 Feb, 2024
  • 11 locations
Study of SAR339375 in Patients With Alport Syndrome

Primary Objectives: To assess the efficacy of SAR339375 in reducing the decline in renal function To assess the safety and tolerability of SAR339375 Secondary Objectives: To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites To assess the immunogenicity of the SAR339375

  • 0 views
  • 19 Feb, 2024
  • 13 locations
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 1-17 years with Systemic Juvenile Idiopathic Arthritis (sJIA) in order to identify the dose and regimen for adequate treatment of this population. Secondary Objective: To describe the pharmacodynamics (PD) profile, the efficacy, and the long term safety …

rheumatism
fever
arthritis
rheumatic diseases
disease modifying antirheumatic drugs
  • 0 views
  • 19 Feb, 2024
  • 30 locations
An Open-label Ascending Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)

Primary Objective: To describe the pharmacokinetic (PK) profile of sarilumab in patients aged 2-17 years with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) in order to identify the dose and regimen for adequate treatment of this population Secondary Objective: To describe the pharmacodynamic (PD) profile, the efficacy and the long-term safety of …

arthritis
rheumatoid factor
anti-rheumatic drugs
sarilumab
disease modifying antirheumatic drugs
  • 0 views
  • 19 Feb, 2024
  • 34 locations
SAR231893-LPS15497- "Dupilumab Effect on Sleep in AD Patients"  

Primary Objective: To evaluate the effect of dupilumab on sleep quality in adult patients with moderate to severe atopic dermatitis (AD) Secondary Objectives: To evaluate the effect of dupilumab on objective and subjective quantitative sleep parameters, AD related outcomes, and daytime consequences of sleep deprivation To continue to assess the …

dupilumab
atopic
dermatitis
sleep disturbances
corticosteroids
  • 0 views
  • 19 Feb, 2024
  • 42 locations
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Primary Objectives: Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared to …

residual tumor
isatuximab
bone marrow plasma cells
smoldering myeloma
residual disease
  • 0 views
  • 24 Nov, 2025
  • 16 locations
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Primary Objectives: Safety run-in: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) Randomized Phase 3: To demonstrate the clinical benefit of isatuximab in combination with lenalidomide and dexamethasone in the prolongation of progression-free survival when compared to …

residual tumor
isatuximab
bone marrow plasma cells
smoldering myeloma
residual disease
  • 0 views
  • 24 Nov, 2025
  • 16 locations
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

Primary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: To characterize the long-term efficacy of fitusiran as assessed by the frequency of: Bleeding episodes Spontaneous bleeding episodes Target joint bleeding episodes To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants …

fitusiran
haemophilia a
antihemophilic factor
hemarthrosis
hemophilia
  • 0 views
  • 19 Feb, 2024
  • 44 locations